QNCX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Quince Therapeutics rebrands as IRulya Therapeutics, focusing on the clinical development of LAM-001 for pulmonary diseasesOct 9, 2026
- Quince Therapeutics reported topline results from Phase 3 NEAT trial of eDSP in ataxia-telangiectasiaJan 30, 2026
- Quince Therapeutics announces last patient last visit in Phase 3 NEAT trial for ataxia-telangiectasiaDec 15, 2025
- Quince Therapeutics announces CPT: Pharmacometrics & Systems Pharmacology publication of eDSP population pharmacokinetic modeling studySep 26, 2025
- Quince Therapeutics completes enrollment in pivotal Phase 3 NEAT trial in ataxia-telangiectasiaJul 16, 2025